Aurobindo Pharma to begin European supplies from China facility in April

The company has secured European regulatory approvals, allowing it to begin product supply

Aurobindo Pharma will commence supplies to Europe from its China-based facility starting April 2025, Business Standard reported, citing the company's Chief Financial Officer Santhanam Subramanian.

The Hyderabad-based pharmaceutical firm initiated operations at the China plant in late November 2024 and is now ramping up production.

"The China plant will start billing sometime in the month of April, mainly to the European markets," Subramanian told analysts in a call, according to Business Standard.

The company has secured European regulatory approvals, allowing it to begin product supply, he added.

"We are in the process of getting it (in China) and after that, there may be an inspection for the US (market) also," Subramanian noted, suggesting potential expansion into the American market.

Aurobindo Pharma anticipates strong growth from the China facility over the next two to three years. However, when asked about revenue projections, Subramanian refrained from giving specific numbers. "This being the first year, we may not like to, but certainly, I see significant revenue coming up in two to three years' time," he stated.

On the company’s biologics business, Aurobindo Pharma Director and CEO of Biologics, Vaccines, and Peptides, Satakarni Makkapati, said the segment is expected to reach a major inflection point between 2028 and 2030.

"We have three products that are approved, two with a positive opinion in Europe, one in the UK, and we expect one more this year. With Denosumab, Omalizumab, and another product coming next year, we anticipate at least seven biosimilars to be fully commercialized by 2027-28," he said.

Makkapati expressed confidence in the company’s long-term biosimilar strategy, emphasizing a measured approach to investments and product selection. "We are enthusiastic about the progress we are making, and we are very sure-footed in our investments and very prudent about the product choices we are making in the biosimilar segment," he added.